Information Provided By: 
Fly News Breaks for March 2, 2018
AXGN
Mar 2, 2018 | 08:37 EDT
Lake Street analyst Bruce Jackson raised his price target for AxoGen to $38 citing solid execution following the company's Q4 results. Management reiterated its full year 2018 guidance for revenue growth of at least 40% with gross margins above 80%, Jackson tells investors in a post-earnings research note. He notes the guidance excludes revenue from new product initiatives like surgical adhesion prevention, breast reconstruction, and lower-limb iatrogenic nerve repair, among others. Jackson reiterates a Buy rating on AxoGen.
News For AXGN From the Last 2 Days
There are no results for your query AXGN
